Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase II Trial of Inhibition of CD26 Peptidase Using Sitagliptin to Enhance Engraftment After Umbilical Cord Blood Transplantation for Adults With Hematological Malignancies

NCT01720264 is registered in ClinicalTrials.gov with Sherif S. Farag as lead sponsor.

NCT NCT01720264
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01720264 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase II Trial of Inhibition of CD26 Peptidase Using Sitagliptin to Enhance Engraftment After Umbilical Cord Blood Transplantation for Adults With Hematological Malignancies
Lead sponsor
Sherif S. Farag
Phase
Phase 2
Overall status
Completed
Start date
November 2, 2012
Completion date
December 15, 2017
Enrollment
15 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoid leukemia, acute myeloid leukemia, hematopoetic myelodysplasia, leukemia, myelogenous, chronic, lymphoma, non-hodgkin